Li, Jialin
Shi, Si
Liu, Jiang
Liang, Chen
Hua, Jie
Meng, Qingcai
Xu, Hang
Wei, Miaoyan
Zhang, Bo
Xu, Jin
Wang, Wei
Yu, Xianjun
Article History
Received: 21 December 2022
Accepted: 13 June 2023
First Online: 17 August 2023
Declarations
:
: The study protocol has been approved by the Clinical Research Ethics Committee of Fudan University Shanghai Cancer Center (Permission number: 2209261-8) (October 2022). The study coordinator will obtain consent from the eligible patients, which will ask for permission for the research team to share relevant data and notice that there is neither anticipated harm nor compensation for trial participation.
: These are available from the corresponding author on request.
: The authors declare that they have no competing interests.